Clinical Trial Update: Quantitative Fluorescence Endoscopy Using Durvalumab-680LT in Esophageal Cancer [Phase 1]

View source ↗

Summary

Phase 1 study evaluating quantitative fluorescence endoscopy with a durvalumab-680LT conjugate in esophageal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer

Drugs mentioned

• Durvalumab-680LT (durvalumab-680LT)

Snippet

Sponsor: University Medical Center Groningen | Conditions: Esophageal Cancer | Phase 1 | Status: COMPLETED